Table 1.
Baseline Characteristics of Patients in Two Groups (n (%))
| Characteristics | Olanzapine Group (n=104) | Aprepitant Group (n=106) | P |
|---|---|---|---|
| Age (years) | 59.26±8.865 | 60.01±10.358 | 0.574 |
| ≥55 | 79 (75.96) | 78 (73.58) | 0.692 |
| Gender | 0.755 | ||
| Female | 40 (38.46) | 43 (40.57) | |
| Male | 64 (61.54) | 63 (59.43) | |
| History of motion sickness | 17 (16.35) | 21 (19.81) | 0.514 |
| History of female pregnancy vomiting | 13 (32.5) | 11 (25.58) | 0.487 |
| Alcohol use | 0.725 | ||
| No consumption | 48 (46.15) | 50 (47.17) | |
| <4 Drinks per week | 38 (36.54) | 34 (32.08) | |
| ≥4 Drinks per week | 18 (17.31) | 22 (20.75) | |
| Smoking index | 0.474 | ||
| No smoking | 39 (37.50) | 47 (44.34) | |
| 0–400 | 13 (12.50) | 9 (8.49) | |
| ≥400 | 52 (50.00) | 50 (47.17) | |
| Type of malignance | 0.755 | ||
| Lung cancer | 40 (38.46) | 43 (40.57) | |
| Others | 64 (61.54) | 63 (59.43) | |
| Chemotherapy cycle | 0.232 | ||
| First cycle | 27 (25.96) | 37 (34.90) | |
| Second cycle | 30 (28.845) | 23 (21.70) | |
| Third cycle | 17 (16.35) | 23 (21.70) | |
| ≥Fouth cycle | 30 (28.845) | 23 (21.70) |